Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin, S. Marktel, M. Bua, R. M. Szydlo, A. Franceschino, I. Nathan, I. Foot, C. Crawley, T. Nakorn Nakorn, E. Olavarria, A. Lennard, A. Neylon, S. G. O'Brien, J. M. Goldman, J. F. Apperley

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.

Original languageEnglish
Pages (from-to)1448-1453
Number of pages6
JournalLeukemia
Volume17
Issue number8
DOIs
StatePublished - 1 Aug 2003
Externally publishedYes

Keywords

  • Chronic myeloid leukaemia
  • Cytogenetic response
  • Imatinib mesylate
  • Neutropenia
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa'. Together they form a unique fingerprint.

Cite this